Review: taking Warfarin sodium and Celebrex together


Summary

Drug interactions are reported among people who take Warfarin sodium and Celebrex together. This review analyzes the effectiveness and drug interactions between Warfarin sodium and Celebrex. It is created by eHealthMe based on reports of 3,914 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Warfarin sodium and Celebrex >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Warfarin Sodium

Warfarin sodium has active ingredients of warfarin sodium. It is often used in atrial fibrillation/flutter. (latest outcomes from Warfarin sodium 48,794 users)

Celebrex

Celebrex has active ingredients of celecoxib. It is often used in arthritis. (latest outcomes from Celebrex 76,608 users)

On Aug, 17, 2016

3,914 people who take Warfarin Sodium, Celebrex are studied.


Number of reports submitted per year:

Warfarin sodium and Celebrex drug interactions.

Drug effectiveness over time:

Warfarin Sodium:
  • < 1 month: 33.0% - (1 of 3 people)
  • 1 - 6 months: 60.0% - (3 of 5 people)
  • 6 - 12 months: 0.0% - (0 of 2 people)
  • 1 - 2 years: 66.0% - (2 of 3 people)
  • 2 - 5 years: 80.0% - (4 of 5 people)
  • 5 - 10 years: 100.0% - (4 of 4 people)
  • 10+ years: 100.0% - (5 of 5 people)
  • not specified: 0.0% - (0 of 0 people)
Celebrex:
  • < 1 month: 33.0% - (1 of 3 people)
  • 1 - 6 months: 57.0% - (4 of 7 people)
  • 6 - 12 months: 0.0% - (0 of 2 people)
  • 1 - 2 years: 20.0% - (1 of 5 people)
  • 2 - 5 years: 33.0% - (2 of 6 people)
  • 5 - 10 years: 25.0% - (1 of 4 people)
  • 10+ years: 0.0% - (0 of 1 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Warfarin Sodium:
  • female: 62.0% - (10 of 16 people)
  • male: 81.0% - (9 of 11 people)
Celebrex:
  • female: 38.0% - (7 of 18 people)
  • male: 20.0% - (2 of 10 people)

Drug effectiveness by age:

Warfarin Sodium:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 50.0% - (1 of 2 people)
  • 40-49: 100.0% - (2 of 2 people)
  • 50-59: 70.0% - (7 of 10 people)
  • 60+: 69.0% - (9 of 13 people)
Celebrex:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 50.0% - (1 of 2 people)
  • 40-49: 50.0% - (1 of 2 people)
  • 50-59: 40.0% - (4 of 10 people)
  • 60+: 21.0% - (3 of 14 people)

Most common drug interactions over time *:

< 1 month:
  • haemorrhage
  • atrial fibrillation
  • pneumonia
  • cerebrovascular accident
  • arrhythmia
  • dyspnoea
  • myocardial infarction
  • cardiac failure congestive
  • hypokalaemia
  • international normalised ratio increased
1 - 6 months:
  • cerebrovascular accident
  • anxiety
  • chest pain
  • death
  • dizziness
  • fall
  • nausea
  • neutropenia
  • thrombocytopenia
  • anhedonia
6 - 12 months:
  • lower gastrointestinal haemorrhage
  • deep vein thrombosis
  • emotional distress
  • injury
  • myocardial infarction
  • pain
  • anaemia
  • asthenia
  • atrial fibrillation
  • electrocardiogram qt prolonged
1 - 2 years:
  • chest pain
  • myocardial infarction
  • dyspnoea
  • cerebrovascular accident
  • dizziness
  • gout
  • international normalised ratio increased
  • back pain
  • blood cholesterol increased
  • blood pressure increased
2 - 5 years:
  • depression
  • dizziness
  • tremor
  • cerebrovascular accident
  • cognitive deterioration
  • fatigue - chronic
  • gait abnormal
  • hyperacusis
  • hyporeflexia
  • loss of sensation, numbness and tingling, paresthesias, sensory loss, tingling and numbness
5 - 10 years:
  • depression
  • cognitive deterioration
  • dizziness
  • fatigue - chronic
  • gait abnormal
  • hyperacusis
  • hyporeflexia
  • loss of sensation, numbness and tingling, paresthesias, sensory loss, tingling and numbness
  • muscle twitching
  • myelomalacia
10+ years:
  • international normalised ratio increased
  • cardiac disorder
  • haematoma
  • haemoglobin decreased
  • abdominal pain upper
  • coagulopathy
  • drug level increased
  • haemorrhage
  • hypotension
  • international normalised ratio decreased
not specified:
  • pain
  • anxiety
  • dyspnoea
  • osteonecrosis of jaw
  • anaemia
  • fatigue
  • injury
  • nausea
  • back pain
  • osteoarthritis

Most common drug interactions by gender *:

female:
  • pain
  • anxiety
  • fall
  • osteonecrosis of jaw
  • anaemia
  • osteoarthritis
  • dyspnoea
  • nausea
  • arthralgia
  • injury
male:
  • pain
  • anxiety
  • dyspnoea
  • pneumonia
  • injury
  • osteonecrosis of jaw
  • fatigue
  • anaemia
  • back pain
  • cardiac failure congestive

Most common drug interactions by age *:

0-1:
  • arthralgia
  • blood lactate dehydrogenase increased
  • hepatic cancer metastatic
  • myalgia
  • oedema peripheral
  • urine colour abnormal
2-9:
  • abasia
  • arthralgia
  • bursitis
  • femur fracture
  • pain in extremity
  • stress fracture
  • cardiac disorder
  • disease recurrence
  • drug ineffective
  • herpes zoster
10-19:
  • abdominal pain
  • asthenia
  • atrial fibrillation
  • bronchitis
  • carcinoid heart disease
  • cardiac failure congestive
  • chest pain
  • drug effect decreased
  • dyspnoea
  • eye inflammation
20-29:
  • pulmonary embolism
  • dyspnoea
  • chest pain
  • abdominal pain
  • cerebrovascular accident
  • paraesthesia
  • pneumonia
  • atelectasis
  • cardiac arrest
  • cardiac failure congestive
30-39:
  • injury
  • pain
  • anxiety
  • pain in extremity
  • abdominal distension
  • feeling abnormal
  • international normalised ratio increased
  • haematuria
  • pleural fibrosis
  • splenomegaly
40-49:
  • pain
  • bone disorder
  • abdominal pain
  • osteomyelitis
  • pain in extremity
  • deep vein thrombosis
  • osteonecrosis of jaw
  • osteoarthritis
  • oedema peripheral
  • primary sequestrum
50-59:
  • pain
  • anxiety
  • osteonecrosis of jaw
  • nausea
  • anaemia
  • fatigue
  • depression
  • pleural effusion
  • bone lesion
  • infection
60+:
  • pain
  • anxiety
  • fall
  • anaemia
  • dyspnoea
  • asthenia
  • injury
  • fatigue
  • atrial fibrillation
  • international normalised ratio increased

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Warfarin sodium and Celebrex?

Can you answer these questions?

More questions for: Warfarin sodium, Celebrex

You may be interested in these reviews

More reviews for: Warfarin sodium, Celebrex

On eHealthMe, Warfarin sodium (warfarin sodium) is often used to treat atrial fibrillation/flutter. Celebrex (celecoxib) is often used to treat arthritis. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.